Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

Identification of Novel CD74-NRG2α Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers

(2020) Shinji Kohsaka et al.   Journal of Thoracic Oncology

ROS1-dependent cancers — biology, diagnostics and therapeutics

(2020) Alexander Drilon et al.   Nature Reviews Clinical Oncology

Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series

(2020) Jacques Cadranel et al.   ONCOLOGIST

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden

(2019) Ryma Benayed et al.   CLINICAL CANCER RESEARCH

Detection of NRG1 Gene Fusions in Solid Tumors

(2019) Sushma Jonna et al.   CLINICAL CANCER RESEARCH

Gene of the Month: Neuregulin-1 fusion positive NSCLC (NRG1+ NSCLC)

(2019) Misako Nagasaka et al.   Journal of Thoracic Oncology

Detection of NRG1 Fusions in Solid Tumors: Rare Gold?

(2019) Anastasios Dimou et al.   CLINICAL CANCER RESEARCH

685TiPA phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours

(2019) A M Schram et al.   ANNALS OF ONCOLOGY

63ONRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib

(2019) Y Goto et al.   ANNALS OF ONCOLOGY

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

(2019) Alexander Drilon et al.   LANCET ONCOLOGY

Selective RET kinase inhibition for patients with RET-altered cancers

(2018) V Subbiah et al.   ANNALS OF ONCOLOGY

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer

(2018) Dong Hoon Shin et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers

(2018) Alexander Drilon et al.   Cancer Discovery

Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression

(2018) Domenico Trombetta et al.   Oncotarget

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

(2018) Alexander Drilon et al.   Cancer Discovery

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers

(2018) Michael Offin et al.   CLINICAL CANCER RESEARCH

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

(2017) Oliver Gautschi et al.   JOURNAL OF CLINICAL ONCOLOGY

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma

(2017) Lucia Anna Muscarella et al.   Journal of Thoracic Oncology

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib

(2017) Parneet K. Cheema et al.   Journal of Thoracic Oncology

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions

(2017) Nathan D. Gay et al.   Journal of Thoracic Oncology

Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

(2017) Chee Khoon Lee et al.   Journal of Thoracic Oncology

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer

(2017) Katerina Ancevski Hunter et al.   Molecular Diagnosis & Therapy

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance

(2017) Alison M. Schram et al.   Nature Reviews Clinical Oncology

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

(2017) Alexander Drilon et al.   Nature Reviews Clinical Oncology

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

Clinical outcomes with pemetrexed-based systemic therapies inRET-rearranged lung cancers

(2016) A. Drilon et al.   ANNALS OF ONCOLOGY

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations

(2016) Yen-Fu Chen et al.   Journal of Thoracic Oncology

Clinical course of stage IV invasive mucinous adenocarcinoma of the lung

(2016) Yoon Jin Cha et al.   LUNG CANCER

Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung

(2016) Dong Hoon Shin et al.   Oncotarget

Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort

(2015) J. Mazières et al.   ANNALS OF ONCOLOGY

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

(2015) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

(2015) Oliver Gautschi et al.   Journal of Thoracic Oncology

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung

(2015) Hyo Sup Shim et al.   Journal of Thoracic Oncology

Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma

(2014) T. Nakaoku et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

(2014) L. Fernandez-Cuesta et al.   CLINICAL CANCER RESEARCH

Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes

(2014) Saravana M. Dhanasekaran et al.   Nature Communications

CD74-NRG1 Fusions in Lung Adenocarcinoma

(2014) L. Fernandez-Cuesta et al.   Cancer Discovery

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

(2013) Alexander Drilon et al.   Cancer Discovery

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

(2012) A. T. Shaw et al.   ANNALS OF ONCOLOGY

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

(2011) D. Ross Camidge et al.   Journal of Thoracic Oncology